Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vildagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 17/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vildagliptin SCHEMBL29369942 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL27193113 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL10031674 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16153676 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665401 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16579 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16823370 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665400 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL671629 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL354910 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310462-A1 | COMBINATION DRUG FOR THE CONTROL AND MANAGEMENT OF TYPE 2 DIABETES MELLITUS | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2023-10-05 | — | — | US | disclosed |
| US-9795592-B2 | Pharmaceutical formulations of vildagliptin | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2017-10-24 | — | — | US | disclosed |
| US-9795592-B2 | Pharmaceutical formulations of vildagliptin | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2017-10-24 | — | — | US | disclosed |
| US-20170014380-A1 | Vildagliptin Formulation Process Under Inert Gas Atmosphere | Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2017-01-19 | — | — | US | disclosed |
| US-20170014380-A1 | Vildagliptin Formulation Process Under Inert Gas Atmosphere | Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2017-01-19 | — | — | US | disclosed |
| US-20170014379-A1 | Pharmaceutical Formulations of Vildagliptin | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2017-01-19 | — | — | US | disclosed |
| US-20170014379-A1 | Pharmaceutical Formulations of Vildagliptin | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2017-01-19 | — | — | US | disclosed |
| US-20160250163-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AS WELL AS METHODS FOR THE DIAGNOSIS/PROGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS | CNIC Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III (ES) | 2016-09-01 | — | — | US | disclosed |
| US-20140302150-A1 | DPP-IV INHIBITOR FORMULATIONS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250163-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AS WELL AS METHODS FOR THE DIAGNOSIS/PROGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS | NES, ADRB3, ADRB1 | DPP4 2733/4885FAP 3806/4885DPP8 4146/4885 |
| US-20170014379-A1 | Pharmaceutical Formulations of Vildagliptin | DPP4, DPP7, SLC5A1 | DPP4 1/4885FAP 191/4885DPP8 5/4885 |
| US-20170014380-A1 | Vildagliptin Formulation Process Under Inert Gas Atmosphere | VIL1, TPSB2, TPSD1 | DPP4 4/4885FAP 59/4885DPP8 25/4885 |
| US-20230310462-A1 | COMBINATION DRUG FOR THE CONTROL AND MANAGEMENT OF TYPE 2 DIABETES MELLITUS | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 381/4885DPP8 5/4885 |
| US-20140302150-A1 | DPP-IV INHIBITOR FORMULATIONS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 20/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.